Hung, P.-Y.; Moerland, J.A.; Leal, A.S.; Aleiwi, B.; Ellsworth, E.; Clapp, D.W.; Staedtke, V.; Bai, R.; Liby, K.T.
The RXR Agonist MSU-42011 Reduces Tumor Burden in a Murine Preclinical NF1-Deficient Model. Cancers 2025, 17, 1920.
https://doi.org/10.3390/cancers17121920
AMA Style
Hung P-Y, Moerland JA, Leal AS, Aleiwi B, Ellsworth E, Clapp DW, Staedtke V, Bai R, Liby KT.
The RXR Agonist MSU-42011 Reduces Tumor Burden in a Murine Preclinical NF1-Deficient Model. Cancers. 2025; 17(12):1920.
https://doi.org/10.3390/cancers17121920
Chicago/Turabian Style
Hung, Pei-Yu, Jessica A. Moerland, Ana S. Leal, Bilal Aleiwi, Edmund Ellsworth, D. Wade Clapp, Verena Staedtke, Renyuan Bai, and Karen T. Liby.
2025. "The RXR Agonist MSU-42011 Reduces Tumor Burden in a Murine Preclinical NF1-Deficient Model" Cancers 17, no. 12: 1920.
https://doi.org/10.3390/cancers17121920
APA Style
Hung, P.-Y., Moerland, J. A., Leal, A. S., Aleiwi, B., Ellsworth, E., Clapp, D. W., Staedtke, V., Bai, R., & Liby, K. T.
(2025). The RXR Agonist MSU-42011 Reduces Tumor Burden in a Murine Preclinical NF1-Deficient Model. Cancers, 17(12), 1920.
https://doi.org/10.3390/cancers17121920